Pregnancy risk

For expectant parents, pregnancy risks can be difficult to assess when deciding whether prenatal screening procedures are worth the potential complications, including loss of the foetus. Our Non-invasive Prenatal Screening procedure is an innovative genetic test for pregnant women at risk of fetal Patau syndrome, Edward's Syndrome, or Down syndrome. These rapid, reliable and safe NIPT tests offer screening options that effectively detect trisomies 13, 18 and 21 while limiting the pregnancy risks associated with procedures such as amniocentesis. Available starting from only the 10^th week of pregnancy, the groundbreaking procedures offer genuine peace of mind.

The NIPT screening kits offered by Eurofins Biomnis test for factors of abnormal pregnancy is carried out by taking a simple maternal blood sample. Aside from maternal DNA, the blood of pregnant women contains fetal DNA originating from the placenta. The identification of fetal DNA in the maternal blood sample, in tandem with a new technology called Next Generation Sequencing that is capable of counting all genetic material sequences in the maternal blood sample, allows for a rapid and accurate detection of factors of abnormal pregnancy, including fetal Patau syndrome (trisomy 13) and Down syndrome (trisomy 21).

Complications during pregnancy remain common, but thanks to rapid medical and technological advancements from companies like ours, they are also increasingly easier to detect. For many expectant parents considering invasive prenatal screening procedures such as amniocentesis tests, the risks associated with such a test can be a source of concern. For that reason, Biomnis has developed a new generation of innovative, entirely non-invasive screening procedures that can be arranged after only 10 weeks of amenorrhoea. With results of the simple maternal blood test available after 7 working days, the NIPT is an efficient and remarkably accurate new way to screen for complications during pregnancy.